| P50 | author | Andrew M Scott | Q59559618 |
| | Thomas John | Q81385845 |
| P2093 | author name string | Gareth Rivalland | |
| P2860 | cites work | A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer | Q22001066 |
| | Rituximab: mechanism of action | Q24607358 |
| | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 |
| | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | Q27853359 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 |
| | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 |
| | Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview | Q28145787 |
| | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial | Q44991597 |
| | Advancing Clinical Trials to Streamline Drug Development | Q46111530 |
| | Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. | Q54486136 |
| | Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r | Q56765596 |
| | Antibody therapy of cancer | Q28262538 |
| | Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 |
| | Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 |
| | Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 |
| | Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 |
| | Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 |
| | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 |
| | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 |
| | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 |
| | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. | Q30275719 |
| | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 |
| | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 |
| | gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma | Q34188859 |
| | Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. | Q34272038 |
| | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 |
| | Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma | Q34563261 |
| | Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). | Q34629364 |
| | Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma | Q34647109 |
| | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 |
| | Predicting analysis times in randomized clinical trials with cancer immunotherapy | Q35910361 |
| | Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST | Q36015295 |
| | Pseudoprogression and Immune-Related Response in Solid Tumors | Q36211586 |
| | FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy | Q36884429 |
| | The misguided ethics of crossover trials | Q37694970 |
| | A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. | Q38593792 |
| | FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. | Q38793230 |
| | Immunotherapy in melanoma: Recent advances and future directions | Q38807845 |
| | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 |
| | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | Q39311439 |
| | Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial | Q39396355 |
| | Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma | Q39534880 |
| | Statistical issues and challenges in immuno-oncology | Q39575240 |
| | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 |
| | Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. | Q40388100 |
| | Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial | Q40692551 |
| | Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. | Q43056663 |
| P433 | issue | 9 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 2164-2178 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Standard of care in immunotherapy trials: Challenges and considerations | |
| P478 | volume | 13 | |